Since the World Health Organization (WHO) declared in March 2020 the recent outbreak of the new coronavirus SARS-CoV-2 causing a severe acute respiratory syndrome (COVID-19), as pandemic, drastic measures have been taken all over the world to protect human populations. The current situation creates a strong need for large screening efforts in order to assess the immune status of the population and to advice decision makers on measures to relaunch social and economic activites.
Based on the competences of the team to set up diagnostic assays and to produce recombinant proteins, we decided to dedicate part of our research to the setup of a high-performance and flexible diagnostic assay using an immunodetection technique and recombinant viral surface proteins expressed and purified in Luxembourg, which can be readily adapted to changing needs, such as the inclusion of newly emerging specific virus strains in routine testing or the targeted monitoring of immune response kinetics in clinical studies.
Project partners: Centre Hospitalier de Luxembourg (CHL), Laboratoire National de Santé (LNS), University of Luxembourg/ Luxembourg Centre for Systems Biomedicine (LCSB), Integrated Biobank of Luxembourg (IBBL), Laboratoires Réunis Luxembourg.
Co-funding: FNR COVID-19 Fast track scheme, project COV-IMMUN